208 related articles for article (PubMed ID: 37686588)
21. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
[TBL] [Abstract][Full Text] [Related]
22. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
[TBL] [Abstract][Full Text] [Related]
23. Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry.
Haist M; Stege H; Lang BM; Tsochataridou A; Salzmann M; Mohr P; Schadendorf D; Ugurel S; Placke JM; Weichenthal M; Gutzmer R; Leiter U; Kaatz M; Haferkamp S; Berking C; Heppt M; Tschechne B; Schummer P; Gebhardt C; Grabbe S; Loquai C
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428636
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
Scheiner B; Roessler D; Phen S; Lim M; Pomej K; Pressiani T; Cammarota A; Fründt TW; von Felden J; Schulze K; Himmelsbach V; Finkelmeier F; Deibel A; Siebenhüner AR; Shmanko K; Radu P; Schwacha-Eipper B; Ebert MP; Teufel A; Djanani A; Hucke F; Balcar L; Philipp AB; Hsiehchen D; Venerito M; Sinner F; Trauner M; D'Alessio A; Fulgenzi CAM; Pinato DJ; Peck-Radosavljevic M; Dufour JF; Weinmann A; Kremer AE; Singal AG; De Toni EN; Rimassa L; Pinter M
JHEP Rep; 2023 Jan; 5(1):100620. PubMed ID: 36578451
[TBL] [Abstract][Full Text] [Related]
25. Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.
Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Hitron EE; Russler GA; Yantorni L; Caulfield S; Brown JT; Goldman JM; Nazha B; Carthon BC; Harris WB; Kucuk O; Master VA; Bilen MA
J Immunother Precis Oncol; 2022 Aug; 5(3):52-57. PubMed ID: 36034580
[TBL] [Abstract][Full Text] [Related]
26. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
27. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer.
Hayashi-Tanner Y; Polewski PJ; Gaddam M; Fisher NR; Kovacs AJ; Marinier DE
J Geriatr Oncol; 2022 Sep; 13(7):1011-1016. PubMed ID: 35637132
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.
Hazama D; Nakahama K; Kodama H; Miyazaki A; Azuma K; Kawashima Y; Sato Y; Ito K; Shiraishi Y; Miura K; Takahama T; Oizumi S; Namba Y; Ikeda S; Yoshioka H; Tsuya A; Yasuda Y; Negi Y; Hara A; Toda M; Tachihara M
JTO Clin Res Rep; 2024 Jan; 5(1):100613. PubMed ID: 38229769
[TBL] [Abstract][Full Text] [Related]
30. Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer.
Zhang S; Pease DF; Kulkarni AA; Kumar M; Shanley RM; Xu B; Joshi SP; Patel MR
Clin Med Insights Oncol; 2021; 15():11795549211004489. PubMed ID: 34248362
[TBL] [Abstract][Full Text] [Related]
31. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
32. Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K; Geurts BS; Zeverijn LJ; van der Noort V; Verheul HMW; Haanen JBAG; van der Veldt AAM; Eskens FALM; Aarts MJB; van Herpen CML; Jalving M; Gietema JA; Devriese LA; Labots M; Barjesteh van Waalwijk van Doorn-Khosrovani S; Smit EF; Bloemendal HJ
Lancet Reg Health Eur; 2024 Apr; 39():100875. PubMed ID: 38464480
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
[No Abstract] [Full Text] [Related]
34. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
35. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
Yoneda T; Sone T; Koba H; Shibata K; Suzuki J; Tani M; Nishitsuji M; Nishi K; Kobayashi T; Shirasaki H; Araya T; Kita T; Kase K; Yamamura K; Terada N; Nishikawa S; Tambo Y; Kimura H; Kasahara K
Clin Lung Cancer; 2022 Sep; 23(6):467-476. PubMed ID: 35618628
[TBL] [Abstract][Full Text] [Related]
37. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
40. A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer.
Abedian Kalkhoran H; Zwaveling J; Storm BN; van Laar SA; Portielje JE; Codrington H; Luijten D; Brocken P; Smit EF; Visser LE
BMC Cancer; 2023 Mar; 23(1):247. PubMed ID: 36918817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
